FourThought Financial Partners LLC Cuts Stock Holdings in Insulet Co. (NASDAQ:PODD)

FourThought Financial Partners LLC cut its holdings in Insulet Co. (NASDAQ:PODD) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,292 shares of the medical instruments supplier’s stock after selling 123 shares during the quarter. FourThought Financial Partners LLC’s holdings in Insulet were worth $1,643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Allianz Asset Management GmbH increased its stake in Insulet by 27.7% in the 4th quarter. Allianz Asset Management GmbH now owns 113,921 shares of the medical instruments supplier’s stock valued at $29,741,000 after purchasing an additional 24,734 shares in the last quarter. ING Groep NV acquired a new position in shares of Insulet in the fourth quarter worth $556,000. Handelsbanken Fonder AB lifted its holdings in Insulet by 9.9% in the 4th quarter. Handelsbanken Fonder AB now owns 18,916 shares of the medical instruments supplier’s stock valued at $4,938,000 after purchasing an additional 1,700 shares in the last quarter. Private Advisor Group LLC grew its stake in Insulet by 30.5% in the 4th quarter. Private Advisor Group LLC now owns 9,642 shares of the medical instruments supplier’s stock worth $2,517,000 after acquiring an additional 2,255 shares during the period. Finally, Alberta Investment Management Corp increased its stake in Insulet by 57.6% in the fourth quarter. Alberta Investment Management Corp now owns 3,400 shares of the medical instruments supplier’s stock valued at $888,000 after purchasing an additional 1,242 shares during the last quarter.

Insulet Stock Performance

Shares of PODD opened at $283.48 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $289.46. The company’s fifty day moving average is $273.33 and its 200-day moving average is $248.46. The firm has a market cap of $19.88 billion, a price-to-earnings ratio of 48.96, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Equities analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PODD. Wells Fargo & Company boosted their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Morgan Stanley boosted their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.